2017
DOI: 10.1021/acsmedchemlett.6b00467
|View full text |Cite
|
Sign up to set email alerts
|

Prototypic 18F-Labeled Argininamide-Type Neuropeptide Y Y1R Antagonists as Tracers for PET Imaging of Mammary Carcinoma

Abstract: The neuropeptide Y (NPY) Y receptor (YR) selective radioligand ()--(2,2-diphenylacetyl)--[4-(2-[F]fluoropropanoylamino)butyl]aminocarbonyl--(4-hydroxybenzyl)argininamide (), derived from the high-affinity YR antagonist BIBP3226, was developed for imaging studies of YR-positive tumors. Starting from the argininamide core bearing amine-functionalized spacer moieties, a series of fluoropropanoylated and fluorobenzoylated derivatives was synthesized and studied for YR affinity. The fluoropropanoylated derivative d… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
23
0

Year Published

2017
2017
2021
2021

Publication Types

Select...
8

Relationship

2
6

Authors

Journals

citations
Cited by 12 publications
(23 citation statements)
references
References 36 publications
0
23
0
Order By: Relevance
“…The difference in affinity between the 111 In-labeled version of pb12 and its nat Tb counterpart illustrates the necessity of carefully determining affinity of metallated compounds for imaging and therapy. Importantly, these nanomolar affinity values compete well with other full-length peptides [17] or non-peptide ligands [21] and are better than those reported for truncated peptides [22].…”
Section: Discussionmentioning
confidence: 51%
See 1 more Smart Citation
“…The difference in affinity between the 111 In-labeled version of pb12 and its nat Tb counterpart illustrates the necessity of carefully determining affinity of metallated compounds for imaging and therapy. Importantly, these nanomolar affinity values compete well with other full-length peptides [17] or non-peptide ligands [21] and are better than those reported for truncated peptides [22].…”
Section: Discussionmentioning
confidence: 51%
“…Targeted radionuclide therapy holds promise to deliver radiation to tumor cells over-expressing peptide receptors. In this work, we aimed to explore the feasibility of enhanced-TRT by using a subcellular active (radio) pharmaceutical able to deliver Auger-electron emitter like 161 Tb, in tumors over-expressing the hY 1 R. Several strategies have been used to develop NPY ligands for imaging and therapy (non-peptide ligands, antagonistictruncated peptides, or agonistic full-length peptides) with variable success [19,21,22]. The full-length hY 1 Rpreferring peptide analog [F 7 ,P 34 ]-NPY allows selective delivery of cargos such as radioisotopes [12,17,23].…”
Section: Discussionmentioning
confidence: 99%
“…As it was described that MCF-7 cells can express the target NPY(Y 1 )R to a much higher extent in vivo than under in vitro conditions [ 34 ], this might also be the case for the T-47D cell line, expressing besides the NPY(Y 1 )R also the for our scientific question important GRPR. Thus, we in the following performed initial in vivo evaluations of HBPL [ 68 Ga] 24 , showing highly promising results in the preceding evaluations.…”
Section: Resultsmentioning
confidence: 85%
“…Such a situation, namely the low number of preclinical or clinical assays reported in the literature [67,68,69,70,71], has been partially ascribed to the in vivo instability of the targeting peptides [72,73,74,75]. Although not as extensively as the peptide receptors mentioned above, neuropeptide Y receptor subtypes 1 (NPYR1) and 2 (NPYR2) have also been studied as imaging targets for NPYR1-expressing tumors such as breast cancer, [76,77,78,79,80,81,82,83,84] and for brain imaging [85], respectively.…”
Section: Introductionmentioning
confidence: 99%